{
    "nct_id": "NCT00203320",
    "title": "Etanercept for Alzheimer's-Type Memory Loss Pilot Study II",
    "status": "COMPLETED",
    "last_update_time": "2006-04-20",
    "description_brief": "It is widely believed that inflammation contributes to the pathogenesis of AD. TNF has been implicated in both AD and neurological inflammation. Anti-TNF therapy is therefore surmised to be of potential benefit for treating AD.",
    "description_detailed": "Etanercept, a biologic anti-TNF fusion protein, will be administered weekly or biweekly by perispinal injection to a maximum of 30 study subjects for a period of one year with serial testing of cognition and function.",
    "phase": [
        "PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted biologic",
    "drug": [
        "Etanercept (Enbrel) \u2014 a biologic TNF-\u03b1 inhibitor (p75 TNF receptor\u2013Fc fusion protein)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests etanercept, a biologic TNF-\u03b1 antagonist, because TNF-mediated neuroinflammation is implicated in AD pathogenesis; the intervention aims to modify disease-related inflammation rather than only provide symptomatic cognitive enhancement. \ue200cite\ue202turn0search0\ue202turn0search3\ue201",
        "Act (extracted details + web evidence): The trial title is 'Etanercept for Alzheimer's-Type Memory Loss Pilot Study II' and the published pilot work describes perispinal administration of etanercept in patients with mild-to-severe AD with reported cognitive improvements over 6 months (open-label, n=15). Etanercept's mechanism is well-described as a soluble TNF receptor fusion protein that binds and neutralizes TNF, reducing inflammatory signaling. Preclinical and clinical reports have investigated etanercept's neuroprotective and anti-inflammatory effects in AD models and small human studies. \ue200cite\ue202turn0search3\ue202turn0search4\ue202turn0search0\ue202turn0search2\ue201",
        "Reflect: Classification rationale \u2014 etanercept is a biologic (not a small molecule) that targets an AD-relevant pathological process (TNF-driven inflammation). Under the provided category definitions this best fits 'disease-targeted biologic' (biologic intervention directed at an AD-related pathogenic mechanism). Note: one could argue it's an anti-inflammatory approach rather than directly anti-amyloid/tau; nevertheless it is a biologic intended to modify disease biology, so 'disease-targeted biologic' is the closest fit. Key supporting sources: pilot clinical report of perispinal etanercept in AD patients and mechanistic descriptions of etanercept (Enbrel). \ue200cite\ue202turn0search3\ue202turn0search0\ue202turn0search4\ue201"
    ],
    "agent_type": "F) Inflammation",
    "explanation_agent": [
        "Reason: The intervention is etanercept (Enbrel), a soluble p75 TNF receptor\u2013Fc fusion protein that binds and neutralizes TNF-alpha to reduce inflammatory signaling. The trial and pilot reports explicitly state the rationale is to inhibit TNF-mediated neuroinflammation implicated in AD pathogenesis. \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search8\ue201",
        "Act: Extracted details: Etanercept (biologic TNF-\u03b1 antagonist; p75 TNFR\u2013Fc fusion) administered perispinally in a small open\u2011label pilot (n=15) with reported cognitive improvements over 6 months; multiple publications and a trial registry entry describe this use and the anti\u2011TNF mechanism. Key sources: Enbrel mechanism page (drug MOA), PubMed pilot study summary, J Neuroinflammation rapid improvement report, BMC Neurology case series, and commentary on perispinal etanercept. \ue200cite\ue202turn0search0\ue202turn0search2\ue202turn0search8\ue202turn0search3\ue202turn0search5\ue201",
        "Reflect: Mapping to CADRO \u2014 the primary biological target/mechanism is modulation of inflammation via TNF-alpha inhibition. Under the CADRO taxonomy this best fits F) Inflammation (not amyloid/tau, not synaptic plasticity as primary, and not a non-therapeutic diagnostic). Although etanercept is a biologic, CADRO categories are organized by biological process/target; therefore 'Inflammation' is the most specific and appropriate CADRO category. \ue200cite\ue202turn0search5\ue201"
    ]
}